Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The price of Kura Oncology Inc (NASDAQ: KURA) closed at $7.33 in the last session, up 1.10% from day before closing price of $7.25. In other words, the price has increased by $1.10 from its previous closing price. On the day, 1.57 million shares were traded.
Ratios:
We take a closer look at KURA’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.81 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 4.42. For the most recent quarter (mrq), Quick Ratio is recorded 9.46 and its Current Ratio is at 9.46. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
On October 24, 2024, UBS started tracking the stock assigning a Buy rating and target price of $27.
Stifel Downgraded its Buy to Hold on October 14, 2024, whereas the target price for the stock was revised from $26 to $19.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 28 ’25 when DOYLE THOMAS JAMES sold 4,949 shares for $7.87 per share. The transaction valued at 38,958 led to the insider holds 88,193 shares of the business.
Leoni Mollie sold 4,963 shares of KURA for $39,068 on Jan 28 ’25. The Chief Medical Officer now owns 88,253 shares after completing the transaction at $7.87 per share. On Jan 28 ’25, another insider, Bair Teresa Brophy, who serves as the Chief Legal Officer of the company, sold 7,281 shares for $7.87 each. As a result, the insider received 57,315 and left with 107,948 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 10.99 while its Price-to-Book (P/B) ratio in mrq is 1.39.
Stock Price History:
Over the past 52 weeks, KURA has reached a high of $24.17, while it has fallen to a 52-week low of $6.98. The 50-Day Moving Average of the stock is -10.11%, while the 200-Day Moving Average is calculated to be -54.25%.
Shares Statistics:
A total of 78.23M shares are outstanding, with a floating share count of 75.15M. Insiders hold about 6.94% of the company’s shares, while institutions hold 96.11% stake in the company.
Earnings Estimates
The current assessment of Kura Oncology Inc (KURA) involves the perspectives of 8.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.59, with high estimates of -$0.07 and low estimates of -$0.87.
Analysts are recommending an EPS of between -$0.28 and -$3.14 for the fiscal current year, implying an average EPS of -$2.12. EPS for the following year is -$1.99, with 10.0 analysts recommending between $0.95 and -$4.79.
Revenue Estimates
Based on 14 analysts’ estimates, the company’s revenue will be $178.59M in the next fiscal year. The high estimate is $451.2M and the low estimate is $7.8M.
